Hatteras

Hatteras is a prescription oral medication that combines the statin atorvastatin with the cholesterol absorption inhibitor ezetimibe. The fixed‑dose combination is formulated for the treatment of elevated cholesterol and mixed dyslipidemia in adults. It belongs to the statin and cholesterol absorption inhibitor class and is marketed in the European Union. The product is taken by mouth and requires a health‑care provider’s prescription in accordance with local clinical guidelines.

Hatteras is indicated for the management of several lipid disorders in adult patients.

- Primary hypercholesterolemia (elevated LDL‑C). - Mixed dyslipidemia (elevated LDL‑C and triglycerides). - Familial hypercholesterolemia when diet and lifestyle alone are insufficient. - Patients who require additional LDL‑C reduction beyond statin monotherapy. - Adjunct therapy after myocardial infarction or stroke to lower cardiovascular risk, if prescribed.

The safety profile of Hatteras reflects the combined effects of atorvastatin and ezetimibe, with most patients experiencing mild, transient events.

Common: - Muscle aches or weakness. - Headache. - Diarrhea or abdominal discomfort. - Elevated liver enzymes (transient). - Nausea or loss of appetite.

Serious: - Rhabdomyolysis or severe muscle breakdown. - Acute liver injury or hepatitis. - Persistent elevation of creatine kinase. - Severe allergic reaction (angioedema, anaphylaxis).

Before initiating Hatteras, clinicians should evaluate patient history and laboratory values to minimize risks.

- Assess baseline liver function tests; avoid use in active liver disease. - Review muscle‑related conditions and avoid in patients with unexplained muscle pain. - Use caution in pregnant or breastfeeding women; safety not established. - Adjust dose in patients with severe renal impairment. - Monitor lipid profile and liver enzymes periodically during therapy. - Consider drug interactions with strong CYP3A4 inhibitors.

Hatteras may interact with other medicines that affect its metabolism or increase the risk of muscle toxicity.

Avoid: - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole). - Fibrates (gemfibrozil) due to heightened rhabdomyolysis risk. - Cyclosporine or tacrolimus, which raise statin concentrations.

Use with caution: - Other lipid‑lowering agents (niacin, omega‑3 fatty acids). - Anticoagulants (warfarin) because of possible INR changes. - Antacids containing aluminum or magnesium may reduce ezetimibe absorption.